ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

2 Reasons to Avoid EHC and 1 Stock to Buy Instead

EHC Cover Image

Over the past six months, Encompass Health’s shares (currently trading at $112.50) have posted a disappointing 6.5% loss, well below the S&P 500’s 14.1% gain. This may have investors wondering how to approach the situation.

Is now the time to buy Encompass Health, or should you be careful about including it in your portfolio? Check out our in-depth research report to see what our analysts have to say, it’s free for active Edge members.

Why Is Encompass Health Not Exciting?

Despite the more favorable entry price, we're sitting this one out for now. Here are two reasons there are better opportunities than EHC and a stock we'd rather own.

1. Long-Term Revenue Growth Disappoints

A company’s long-term sales performance is one signal of its overall quality. Any business can put up a good quarter or two, but the best consistently grow over the long haul. Over the last five years, Encompass Health grew its sales at a mediocre 4.7% compounded annual growth rate. This was below our standard for the healthcare sector.

Encompass Health Quarterly Revenue

2. Free Cash Flow Margin Dropping

Free cash flow isn't a prominently featured metric in company financials and earnings releases, but we think it's telling because it accounts for all operating and capital expenses, making it tough to manipulate. Cash is king.

As you can see below, Encompass Health’s margin dropped by 1.3 percentage points over the last five years. Continued declines could signal it is in the middle of an investment cycle. Encompass Health’s free cash flow margin for the trailing 12 months was 13.3%.

Encompass Health Trailing 12-Month Free Cash Flow Margin

Final Judgment

Encompass Health isn’t a terrible business, but it doesn’t pass our bar. After the recent drawdown, the stock trades at 20× forward P/E (or $112.50 per share). This valuation is reasonable, but the company’s shakier fundamentals present too much downside risk. We're pretty confident there are superior stocks to buy right now. We’d recommend looking at the most dominant software business in the world.

High-Quality Stocks for All Market Conditions

Your portfolio can’t afford to be based on yesterday’s story. The risk in a handful of heavily crowded stocks is rising daily.

The names generating the next wave of massive growth are right here in our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.

Recent Quotes

View More
Symbol Price Change (%)
AMZN  222.26
-0.30 (-0.13%)
AAPL  273.75
-0.86 (-0.31%)
AMD  198.48
-10.69 (-5.11%)
BAC  54.66
-0.15 (-0.26%)
GOOG  298.27
-9.46 (-3.07%)
META  654.05
-3.10 (-0.47%)
MSFT  478.60
+2.21 (0.46%)
NVDA  171.57
-6.15 (-3.46%)
ORCL  178.11
-10.54 (-5.59%)
TSLA  471.00
-18.88 (-3.85%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.